We read with interest the paper by Chan et al1 on the effects of resuming aspirin on clinical outcomes in patients with lower gastrointestinal bleeding (LGIB).1 In a retrospective study on patients who had LGIB on aspirin, the authors found that patients who resumed aspirin had a higher risk of recurrent bleeding, but a lower risk of serious cardiovascular events, cardiovascular mortality and, interestingly, mortality owing to sepsis, renal failure, or cancer.